Start with the study design, population, outcomes, limitations, and open questions—not a verdict. Every factual sentence is pinned to an explicitly reviewed source snapshot.
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 14, 2026
Last integrity check
September 14, 2026
Latest notice date
None registered
ACTIVE reported fewer new vertebral and nonvertebral fractures with abaloparatide than placebo in postmenopausal women. Its extension studied subsequent alendronate in both groups. ATOM reported greater bone-density gains in men; that endpoint does not by itself establish fracture reduction in men.↗↗↗
4 reviewed sources4 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The EPP trials reported longer pain-free sunlight exposure. Evidence in vitiligo concerns combination treatment with phototherapy; the six-person stroke study cannot establish treatment benefit or safety. Results from these different settings should not be pooled.↗↗↗↗
5 reviewed sources5 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Early trials reported weight reductions but were designed primarily to assess safety and tolerability. Later zenagamtide studies reported improved glycated hemoglobin in type 2 diabetes. Gastrointestinal adverse events and study discontinuations matter when interpreting these findings.↗↗↗↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
August 18, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
This source set contains a two-person uncontrolled safety pilot, a narrative review dominated by preclinical research, and a recruiting Phase 2 protocol with no posted results. It does not establish human efficacy.↗↗↗
Conditions
Safety observations · Acute hamstring strain
Population
Healthy adults · Adults with acute injury
Design
Uncontrolled study · Trial protocol · Narrative review
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
RECONNECT reported improvements in desire and related distress in premenopausal women with hypoactive sexual desire disorder. Nausea, flushing and headache were more frequent with bremelanotide. Safety analyses overlap the efficacy-trial population.↗↗↗
Conditions
Hypoactive sexual desire disorder · Female sexual dysfunction
6 reviewed sources6 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
August 1, 2026
The selected cagrilintide-alone study reported weight reduction. Later combination trials reported weight or glycemic improvements, but their results cannot be attributed to cagrilintide alone. Gastrointestinal adverse events were common, and a correction to REIMAGINE 2 remains to be reconciled.↗↗↗↗↗↗
3 reviewed sources3 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The studies reported sustained growth hormone and IGF-I responses, including preserved hormone pulsatility. They do not establish clinical benefit for injury recovery, body composition or aging, or long-term safety.↗↗
Conditions
Growth hormone physiology
Population
Healthy adults
Design
Randomized controlled trial · Before-and-after physiology study
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
REWIND reported fewer composite cardiovascular events with dulaglutide; all-cause mortality did not differ significantly. AWARD-PEDS reported improved glycemic control without a between-group BMI benefit. AWARD-7 studied a kidney-disease population, with glycemic control as its primary outcome.↗↗↗
Conditions
Type 2 diabetes · Cardiovascular outcomes · Chronic kidney disease
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The randomized Barth syndrome study did not meet its two primary endpoints; later uncontrolled follow-up reported improvements. The larger MMPOWER-3 trial in primary mitochondrial myopathy also missed its primary endpoints. These populations and study designs must be considered separately.↗↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The two reports differ: one described improved sleep and daytime measures, while the other found weak objective changes and no improvement in subjective sleep quality. These small studies do not establish durable benefit or adequately characterize harms.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
Not available
Latest notice date
None registered
These reports describe retinal findings and changes in melatonin-related or gene-expression measurements. Their abstracts do not provide enough detail to establish a reliable treatment effect, long-term safety or an effect on human lifespan.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The short monotherapy trial reported improved glycated hemoglobin and weight measures. The larger outcomes trial established cardiovascular noninferiority but did not meet its superiority criterion for major cardiovascular events.↗↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The selected topical studies had different findings: the ulcer study reported improved closure, while the small post-laser study found no objective advantage in erythema or skin appearance. The uncontrolled hair study cannot attribute changes to GHK-Cu alone or establish the safety of other injected formulations.↗↗↗
Conditions
Diabetic neuropathic ulcers · Post-laser skin care · Hair loss
Population
Patients with diabetic ulcers · Patients after laser resurfacing · Patients with hair loss
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Controlled studies found high recovery rates after experimentally induced hypoglycemia. A small uncontrolled study also reported recovery during spontaneous episodes. Laboratory recovery times and trained-caregiver observations do not establish equivalent performance in every emergency.↗↗↗
4 reviewed sources4 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The postoperative-ileus trial found no statistically significant improvement in its key or secondary efficacy analyses. The healthy-volunteer study measured growth hormone responses, which do not establish clinical benefit. The additional urine studies concern detection and receptor binding, not therapeutic benefit.↗↗↗↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
CLARINET found longer progression-free survival, without a demonstrated overall-survival or quality-of-life difference. The acromegaly study reported tumor and hormone changes but did not reject its prespecified primary null hypothesis.↗↗↗
Conditions
Neuroendocrine tumors · Acromegaly
Population
Adults
Design
Randomized controlled trial · Open-label extension · Single-arm study
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
In the reviewed pelvic-pain trial, both treatment groups improved without a significant between-group difference. In the prostate-cancer trial, the oral comparator produced more sustained testosterone suppression than leuprolide; that biochemical endpoint does not establish a difference in cancer survival.↗↗
Conditions
Endometriosis-associated pelvic pain · Advanced prostate cancer
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Randomized trials reported improved bowel-movement measures over 12 weeks. Diarrhea is an important adverse effect; the pediatric trial included a serious dehydration event related to severe diarrhea.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The reviewed weight-management trial reported greater mean weight reduction than placebo, and the reviewed cardiovascular trial reported fewer primary cardiovascular events in a high-risk type 2 diabetes population. The findings remain specific to the studied populations and trial conditions.↗↗
Conditions
Obesity · Overweight · Type 2 diabetes · Cardiovascular outcomes
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
ELIXA met cardiovascular noninferiority but did not demonstrate cardiovascular superiority. A smaller Parkinson trial reported less motor-score worsening over 12 months, with gastrointestinal adverse effects; it does not establish neuroprotection or a new approved indication.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The phase 2 trial reported greater weight reduction than placebo over 52 weeks in participants with obesity, with or without type 2 diabetes. Gastrointestinal events were common. These results do not establish long-term clinical outcomes or an approved indication.↗↗
4 reviewed sources4 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Randomized trials reported weight and glucose-control improvements in the studied populations, with gastrointestinal adverse events. These publications do not by themselves establish regulatory status, long-term complications or comparative effectiveness outside their specific designs.↗↗↗↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Human studies associate endogenous MOTS-c with exercise or vascular measurements. Exercise interventions and biomarker associations do not demonstrate the efficacy or safety of administered MOTS-c.↗↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
March 1, 2022
The short trial reported reduced growth-hormone and insulin-like growth factor I levels with octreotide. In the selected-responder Phase 3 trial, oral octreotide met the prespecified noninferiority criterion against injectable therapy for maintaining biochemical response.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The extension reported liver-fat reductions among selected continuing participants. IMPACT met its MASH-resolution endpoint at 24 weeks but did not demonstrate its fibrosis-improvement endpoint. Longer-term clinical outcomes remain unestablished.↗↗
The trials reported weight reductions and predominantly mild gastrointestinal adverse events. The early-phase design and limited follow-up do not establish long-term benefit or superior tolerability to another medicine.↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The trials found more participants met prespecified bowel-response endpoints with plecanatide than placebo. Diarrhea occurred more often with active treatment; these 12-week studies do not establish comparative superiority to other medicines.↗↗↗
Conditions
Chronic idiopathic constipation · Irritable bowel syndrome with constipation
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Year-long trials reported modest HbA1c and weight changes compared with placebo added to insulin. Nausea was common. The automated-delivery study met its glucose-control noninferiority objective but did not improve its emotional-burden endpoint.↗↗↗
3 reviewed sources3 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
Selected trials reported weight reduction and improved glycated hemoglobin. The newer phase 3 diabetes study supports a glycemic effect in its studied population, but these reports do not establish prevention of long-term complications; gastrointestinal adverse events and discontinuations matter.↗↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 18, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
In the reviewed trials, semaglutide was associated with greater weight reduction than placebo in adults without diabetes, and fewer major cardiovascular events in adults with established cardiovascular disease and overweight or obesity without diabetes. The findings apply to those studied populations and trial conditions.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
February 1, 2023
The reviewed studies reported substantial weight reductions in some participants with specific genetic diagnoses. The cohorts were very small, and the Bardet-Biedl and Alström trial reported inconclusive results for the Alström subgroup.↗↗
4 reviewed sources4 study sectionsv2 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
August 25, 2026
Selected studies reported improvements in weight or liver-related measurements. The newer phase 3 reports also found frequent gastrointestinal adverse events. These measured changes do not establish every long-term clinical benefit, and linked correction notices remain relevant to interpretation.↗↗↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
Both reviewed trials reported fewer new vertebral fractures with teriparatide than with the comparator. The active-comparator trial did not find a statistically significant difference for its nonvertebral fragility-fracture endpoint.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
None registered
The reviewed trials reported reductions in visceral adipose tissue, and the smaller trial also reported a modest reduction in liver fat. These studies do not establish long-term clinical outcomes or effects outside the studied HIV populations.↗↗
2 reviewed sources2 study sectionsv1 current review
Reviewed through
August 19, 2026
Last integrity check
August 19, 2026
Latest notice date
July 17, 2021
The reviewed obesity trial reported greater weight reduction with tirzepatide than placebo, and the reviewed type 2 diabetes trial reported lower glycated hemoglobin and body weight than placebo. These trials do not answer every population, long-term outcome, or post-discontinuation question.↗↗
3 reviewed sources3 study sectionsv1 current review
Reviewed through
September 15, 2026
Last integrity check
September 15, 2026
Latest notice date
None registered
The trials reported greater short-term pain-score improvements than placebo, with neurological and other adverse effects. Differences in trial duration and exposure schedules limit comparisons among studies.↗↗↗